What question did this study set out to answer?

The aim is to investigate the frequency of phosphorylated alpha-synuclein deposition in patients with REM sleep behavior disorder (iRBD) and its impact on phenoconversion to synucleinopathy.

March 12, 2026Biomarkers in Medicine0 citations

View Full Paper

The Syn-sleep trial protocol: detection of cutaneous phosphorylated alpha-synuclein in REM sleep behavior disorder

SMSarrah Marcotte TLTodd Levine RFR. FreemanBeth Israel Deaconess Medical Center

Key Points

The aim is to investigate the frequency of phosphorylated alpha-synuclein deposition in patients with REM sleep behavior disorder (iRBD) and its impact on phenoconversion to synucleinopathy.
Defined the trial protocol for detecting phosphorylated alpha-synuclein
Focused on patients with idiopathic REM sleep behavior disorder (iRBD)
Assessed the relationship between α-synuclein deposition and risk of phenoconversion
Identified the frequency of cutaneous phosphorylated alpha-synuclein among participants
Highlighted the potential for α-synuclein deposition to indicate risk of developing synucleinopathies

Abstract

Patients with iRBD are an important population to study due to the high rates of phenoconversion to clinically apparent synucleinopathy. Defining the frequency of P-SYN deposition and the risk of phenoconversion will aid in the development of future clinical trials that seek to alter the natural history of synucleinopathies.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Marcotte et al. (Tue,) studied this question.

synapsesocial.com/papers/69b25b0996eeacc4fcec9548 https://doi.org/https://doi.org/10.1080/17520363.2026.2641474

Perguntar à IA

Bookmark

View Full Paper